Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate

Seetha Venkateswaran, David Margel, Stanley Yap, Karen Hersey, Paul Yip, Neil Eric Fleshner

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: The prostate secretes enzymes and nutrients to promote sperm motility. Recent reports suggest that the prostate may also secrete testosterone, which is believed to be a fuel for prostate tumour growth. The aim of this study was to determine if a difference in serum testosterone levels exists between men on luteinizing hormone releasing-hormone (LHRH) agonists who have undergone radical prostatectomy, radiation or hormone therapy as primary prostate cancer treatment. Methods: Serum testosterone levels were evaluated in 165 consecutive prostate cancer patients using LHRH analogues for >3 months. We excluded patients receiving either radiation or chemotherapy at time of time of testosterone measurement. Patients were classified based on primary treatment: (1) radical prostatectomy; (2) radiation; or (3) primary hormone therapy. We used one-way ANOVA to compare testosterone levels. Pearson correlation was used to correlate testosterone with prostate-specific antigen (PSA) and time on LHRH agonists. Multivariable linear regression was used to predict serum testosterone levels. Results: The median (interquartile range) serum testosterone levels were 1.4 (1-1.9), 1.3 (1-1.625) and 1.25 (0.9-1.525) nmol/L for radical prostatectomy, radiation and primary hormone therapy groups, respectively. There was no statistically significant difference in testosterone levels between the groups (p=0.3). No correlation was found between testosterone and PSA levels or time on LHRH (r=0.02 and r=0.01), respectively. Multivariable linear regression showed that none of the clinical variables were predictors of serum testosterone levels. Conclusion: Our study suggests that primary treatment does not affect serum testosterone levels among men using LHRH analogues.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalJournal of the Canadian Urological Association
Volume6
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Gonadotropin-Releasing Hormone
Testosterone
Prostate
Prostatic Neoplasms
Serum
Therapeutics
Prostatectomy
Radiation
Hormones
Prostate-Specific Antigen
Linear Models
Sperm Motility
Group Psychotherapy
Analysis of Variance
Drug Therapy
Food

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. / Venkateswaran, Seetha; Margel, David; Yap, Stanley; Hersey, Karen; Yip, Paul; Fleshner, Neil Eric.

In: Journal of the Canadian Urological Association, Vol. 6, No. 3, 06.2012, p. 183-186.

Research output: Contribution to journalArticle

@article{b1aad7e89700492185f60244236f80dc,
title = "Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate",
abstract = "Introduction: The prostate secretes enzymes and nutrients to promote sperm motility. Recent reports suggest that the prostate may also secrete testosterone, which is believed to be a fuel for prostate tumour growth. The aim of this study was to determine if a difference in serum testosterone levels exists between men on luteinizing hormone releasing-hormone (LHRH) agonists who have undergone radical prostatectomy, radiation or hormone therapy as primary prostate cancer treatment. Methods: Serum testosterone levels were evaluated in 165 consecutive prostate cancer patients using LHRH analogues for >3 months. We excluded patients receiving either radiation or chemotherapy at time of time of testosterone measurement. Patients were classified based on primary treatment: (1) radical prostatectomy; (2) radiation; or (3) primary hormone therapy. We used one-way ANOVA to compare testosterone levels. Pearson correlation was used to correlate testosterone with prostate-specific antigen (PSA) and time on LHRH agonists. Multivariable linear regression was used to predict serum testosterone levels. Results: The median (interquartile range) serum testosterone levels were 1.4 (1-1.9), 1.3 (1-1.625) and 1.25 (0.9-1.525) nmol/L for radical prostatectomy, radiation and primary hormone therapy groups, respectively. There was no statistically significant difference in testosterone levels between the groups (p=0.3). No correlation was found between testosterone and PSA levels or time on LHRH (r=0.02 and r=0.01), respectively. Multivariable linear regression showed that none of the clinical variables were predictors of serum testosterone levels. Conclusion: Our study suggests that primary treatment does not affect serum testosterone levels among men using LHRH analogues.",
author = "Seetha Venkateswaran and David Margel and Stanley Yap and Karen Hersey and Paul Yip and Fleshner, {Neil Eric}",
year = "2012",
month = "6",
doi = "10.5489/cuaj.11278",
language = "English (US)",
volume = "6",
pages = "183--186",
journal = "Journal of the Canadian Urological Association",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "3",

}

TY - JOUR

T1 - Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate

AU - Venkateswaran, Seetha

AU - Margel, David

AU - Yap, Stanley

AU - Hersey, Karen

AU - Yip, Paul

AU - Fleshner, Neil Eric

PY - 2012/6

Y1 - 2012/6

N2 - Introduction: The prostate secretes enzymes and nutrients to promote sperm motility. Recent reports suggest that the prostate may also secrete testosterone, which is believed to be a fuel for prostate tumour growth. The aim of this study was to determine if a difference in serum testosterone levels exists between men on luteinizing hormone releasing-hormone (LHRH) agonists who have undergone radical prostatectomy, radiation or hormone therapy as primary prostate cancer treatment. Methods: Serum testosterone levels were evaluated in 165 consecutive prostate cancer patients using LHRH analogues for >3 months. We excluded patients receiving either radiation or chemotherapy at time of time of testosterone measurement. Patients were classified based on primary treatment: (1) radical prostatectomy; (2) radiation; or (3) primary hormone therapy. We used one-way ANOVA to compare testosterone levels. Pearson correlation was used to correlate testosterone with prostate-specific antigen (PSA) and time on LHRH agonists. Multivariable linear regression was used to predict serum testosterone levels. Results: The median (interquartile range) serum testosterone levels were 1.4 (1-1.9), 1.3 (1-1.625) and 1.25 (0.9-1.525) nmol/L for radical prostatectomy, radiation and primary hormone therapy groups, respectively. There was no statistically significant difference in testosterone levels between the groups (p=0.3). No correlation was found between testosterone and PSA levels or time on LHRH (r=0.02 and r=0.01), respectively. Multivariable linear regression showed that none of the clinical variables were predictors of serum testosterone levels. Conclusion: Our study suggests that primary treatment does not affect serum testosterone levels among men using LHRH analogues.

AB - Introduction: The prostate secretes enzymes and nutrients to promote sperm motility. Recent reports suggest that the prostate may also secrete testosterone, which is believed to be a fuel for prostate tumour growth. The aim of this study was to determine if a difference in serum testosterone levels exists between men on luteinizing hormone releasing-hormone (LHRH) agonists who have undergone radical prostatectomy, radiation or hormone therapy as primary prostate cancer treatment. Methods: Serum testosterone levels were evaluated in 165 consecutive prostate cancer patients using LHRH analogues for >3 months. We excluded patients receiving either radiation or chemotherapy at time of time of testosterone measurement. Patients were classified based on primary treatment: (1) radical prostatectomy; (2) radiation; or (3) primary hormone therapy. We used one-way ANOVA to compare testosterone levels. Pearson correlation was used to correlate testosterone with prostate-specific antigen (PSA) and time on LHRH agonists. Multivariable linear regression was used to predict serum testosterone levels. Results: The median (interquartile range) serum testosterone levels were 1.4 (1-1.9), 1.3 (1-1.625) and 1.25 (0.9-1.525) nmol/L for radical prostatectomy, radiation and primary hormone therapy groups, respectively. There was no statistically significant difference in testosterone levels between the groups (p=0.3). No correlation was found between testosterone and PSA levels or time on LHRH (r=0.02 and r=0.01), respectively. Multivariable linear regression showed that none of the clinical variables were predictors of serum testosterone levels. Conclusion: Our study suggests that primary treatment does not affect serum testosterone levels among men using LHRH analogues.

UR - http://www.scopus.com/inward/record.url?scp=84862751131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862751131&partnerID=8YFLogxK

U2 - 10.5489/cuaj.11278

DO - 10.5489/cuaj.11278

M3 - Article

C2 - 22664629

AN - SCOPUS:84862751131

VL - 6

SP - 183

EP - 186

JO - Journal of the Canadian Urological Association

JF - Journal of the Canadian Urological Association

SN - 1911-6470

IS - 3

ER -